Duru, Ilhan Cem
Lecomte, Alexandre
Shishido, Tânia Keiko
Laine, Pia
Suppula, Joni
Paulin, Lars
Scheperjans, Filip
Pereira, Pedro A. B.
Auvinen, Petri
Funding for this research was provided by:
Novo Nordisk Foundation (NNF22OC0080109)
Research Council of Finland
Article History
Received: 13 March 2024
Accepted: 8 August 2024
First Online: 14 August 2024
Competing interests
: FS: Grants from The Academy of Finland, The Hospital District of Helsinki and Uusimaa, OLVI-Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, The Wilhelm and Else Stockmann Foundation, The Emil Aaltonen Foundation, The Yrjö Jahnsson Foundation, The Sigrid Jusélius Foundation, Renishaw. Honoraria: AbbVie, Axial Biotherapeutics, Orion, GE Healthcare, Merck, Teva, Bristol Myers Squibb, Sanofi, Biocodex, Lundbeck, and Biogen. Founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd. Member of the advisory boards of Axial Biotherapeutics and MRM Health. Stock options from Axial Biotherapeutics. P.A.B.P., L.P., P.A., and F.S. have patents issued (FI127671B, US10139408B2, US11499971B2) and pending (US16/186,663, EP3149205) that are assigned to NeuroBiome Ltd. T.K.S. is funded by Novo Nordisk Foundation (NNF22OC0080109).